Drug Profile
Ovarian cancer vaccine - MabVax/MSKCC
Alternative Names: MV-Ovar; NSC-748933; Polyvalent vaccine-KLH conjugate - MabVaxLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Gynecologic Oncology Group; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA)
- Class Cancer vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Ovarian cancer
Most Recent Events
- 10 Jun 2015 Phase-II development in Ovarian cancer is ongoing in the US
- 08 Jul 2014 MabVax Therapeutics merged with a wholly-owned subsidiary of Telik
- 28 May 2013 Memorial Sloan-Kettering Cancer Center completes enrolment in its phase II trial for Ovarian cancer in USA (NCT00857545)